Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Treatment of thyroid cancer with radioactive iodine
What radioactive iodine therapy is and how it destroys thyroid cancer cells, what the evidence says about its effectiveness, who qualifies and who does not, what the treatment involves step by step, approximate costs in Turkey versus the UK, US and Germany, recovery milestones including radiation precautions, realistic results and known risks, and how to choose a centre for treatment abroad.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Treatment of Thyroid Cancer with Radioactive Iodine
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is treatment of thyroid cancer with radioactive iodine?
Treatment of thyroid cancer with radioactive iodine (also written RAI or I-131 therapy) uses a radioactive form of iodine — iodine-131 — to destroy thyroid cancer cells. The thyroid gland, and most differentiated thyroid cancers that arise from it, absorb iodine almost exclusively; no other tissue in the body takes it up to the same degree. When a patient swallows a capsule or liquid containing iodine-131, the radioactive material concentrates in any remaining thyroid tissue or cancer cells and delivers a localised dose of radiation that destroys them. The rest of the body receives a comparatively small dose. This biological selectivity is what makes RAI useful and distinguishes it from external-beam radiotherapy, which targets a wider field. For the broader context of oncology treatments in Turkey, including other approaches used alongside or after RAI, see our hub page.
RAI is not used for every thyroid cancer: it works specifically on differentiated thyroid cancers — papillary and follicular — because these tumour types retain the ability to absorb iodine. Medullary and anaplastic thyroid cancers do not absorb iodine and are managed differently. This guide covers how the treatment works, what the evidence says, who is a suitable candidate, what the procedure involves, approximate costs, what recovery looks like and how to choose a centre.
How does radioactive iodine therapy destroy thyroid cancer cells?
Iodine-131 decays by emitting beta particles — high-energy electrons that travel only about 1–2 mm in tissue. Because the radioactive iodine has concentrated inside thyroid cells or cancer deposits, the beta radiation damages the DNA of those cells from within, causing them to die without heavily irradiating the surrounding organs. A small amount of gamma radiation is also emitted, which is what radiation-detection equipment can track using a whole-body scan to confirm where the iodine has gone.
The sequence is usually: total or near-total thyroidectomy first (surgery to remove the thyroid gland), followed weeks later by RAI to ablate any residual thyroid tissue and microscopic cancer cells left behind — a process called remnant ablation. In higher-risk cases RAI is used to treat known lymph-node or distant metastases as well. The dose given (measured in millicuries or megabecquerels) is set by the nuclear medicine or endocrinology team based on the cancer stage, risk category and body weight.
What does the evidence say — does radioactive iodine work?
For low- to intermediate-risk papillary and follicular thyroid cancer, RAI remnant ablation after surgery is well established and endorsed by major clinical guidelines including those of the American Thyroid Association (ATA) and the European Thyroid Association (ETA). Studies consistently show that RAI reduces the rate of recurrence in patients with moderate or high risk features such as larger tumours, lymph-node involvement or incomplete surgical resection.
For very low-risk tumours confined to the thyroid, guidelines now acknowledge that RAI may add little benefit beyond surgery alone, and some patients in this group are managed with active surveillance rather than ablation. This reflects more careful patient selection rather than any weakness in the treatment itself. For metastatic differentiated thyroid cancer, particularly lung or bone metastases that still absorb iodine, repeated RAI courses can achieve meaningful disease control and, in some patients, remission. The evidence is weakest for RAI in cancers that have lost the ability to absorb iodine (so-called radioiodine-refractory disease), where alternative systemic treatments are used instead.
Who is a good candidate, and who is not?
RAI is appropriate for most patients with differentiated (papillary or follicular) thyroid cancer who have had their thyroid surgically removed and whose cancer is classified as intermediate or high risk — based on tumour size, extension beyond the capsule, lymph-node spread or distant metastases. It is also used in some low-risk patients where complete tumour removal was uncertain.
You are less likely to be offered RAI if: you have a very small, low-risk papillary microcarcinoma fully removed by surgery; you have medullary or anaplastic thyroid cancer; your tumour no longer absorbs iodine (radioiodine-refractory); or you are pregnant or breastfeeding, as iodine-131 crosses the placenta and enters breast milk. Women of childbearing age are advised to avoid pregnancy for six to twelve months after treatment. Men are similarly advised to delay conception for several months. The nuclear medicine specialist will review your pathology, staging and TSH stimulation level before recommending a dose.
The RAI procedure step by step
Preparation begins two to four weeks before the capsule is given. Because thyroid cells absorb iodine only when stimulated by thyroid-stimulating hormone (TSH), the team must raise your TSH level. This is done in one of two ways: either you stop taking thyroid hormone replacement (levothyroxine) for three to four weeks, which causes hypothyroidism and fatigue, or you receive injections of recombinant TSH (rhTSH, brand name Thyrogen) over two days while continuing your medication — the preferred option when available as it avoids prolonged symptoms. A low-iodine diet for one to two weeks before treatment further improves uptake by depleting the body's iodine stores.
On the day of treatment you swallow a single capsule or drink a measured liquid containing iodine-131 in a shielded room. The procedure itself takes only a few minutes. Because you are temporarily radioactive, most centres require an isolation period of one to three days — either as an inpatient in a lead-lined room or at home if the dose is below the threshold your country's radiation protection regulations allow for home discharge. During this period you must maintain distance from others (especially children and pregnant women), use separate towels and cutlery, flush the toilet twice, and avoid close contact. The team gives you a detailed written list of precautions. A whole-body scan is performed two to seven days later to confirm where the iodine has concentrated.
Approximate cost of radioactive iodine therapy in Turkey compared with the UK, US and Germany
Costs vary with the dose prescribed, the number of treatment days, whether Thyrogen injections are used (they add to the cost), inpatient versus outpatient administration and what follow-up scanning is included. The figures below are approximate ranges; each centre confirms its own price in a written quote. For a full picture of how our process works before you request a quote, see the linked page.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,500 – €5,000 |
| United Kingdom | €4,000 – €12,000 |
| United States | €5,000 – €18,000 |
| Germany | €4,500 – €13,000 |
What drives the price: the prescribed dose (low-dose remnant ablation costs less than a high-dose treatment for metastatic disease), Thyrogen versus levothyroxine-withdrawal preparation, the number of nights in an isolation room, the whole-body scan and reporting, pre-treatment blood tests (TSH, thyroglobulin, thyroglobulin antibodies), and any consultations included in the package. Ask for an itemised written quote that specifies which of these are included and what is charged separately.
How does RAI compare with other treatments for differentiated thyroid cancer?
Radioactive iodine is not a standalone treatment; it follows surgery and is part of a combined approach. The table below sets it against the other modalities used in thyroid cancer management so you can understand where it fits. For certain complex or recurrent cases, technologies such as gamma knife stereotactic radiosurgery or tomotherapy may be discussed by the multidisciplinary team.
| Modality | Best suited to | Typical limits |
|---|---|---|
| Radioactive iodine (I-131) | Differentiated thyroid cancer (papillary/follicular) after thyroidectomy; iodine-avid metastases | No effect on medullary, anaplastic or radioiodine-refractory cancers |
| External-beam radiotherapy (e.g. tomotherapy) | Locally advanced disease, iodine-refractory recurrence in the neck, bone metastases | Wider radiation field; not thyroid-specific |
| Targeted therapy / TKIs | Radioiodine-refractory metastatic differentiated cancer; medullary cancer | Oral drugs with systemic side effects; not curative in most cases |
Recovery milestones and radiation precautions
The most distinct feature of RAI recovery is the radiation isolation period, not surgical recovery. If you are treated as an inpatient, you typically spend one to three nights in a monitored room before the radiation level falls below the discharge threshold. If you are treated as an outpatient with a lower dose, you go home the same day but must follow the precautions given to you in writing: sleep apart from a partner for several nights, avoid being near children or pregnant people for up to a week, avoid public transport for one to two days and return to work (desk-based) after three to five days in many cases. Salivary glands can be affected — sucking hard sweets and drinking plenty of water in the first 24 hours helps keep saliva moving and reduce gland swelling.
Thyroid hormone replacement (levothyroxine) is started or adjusted after treatment at a TSH-suppressive dose for higher-risk patients. Fatigue from the hypothyroid preparation period resolves once your replacement dose is established, usually within two to four weeks. A follow-up thyroglobulin blood test and, if indicated, a diagnostic whole-body scan at six to twelve months assesses the response to treatment.
Realistic results: what to expect before and after RAI
The primary measure of success after RAI is an undetectable or very low serum thyroglobulin level (the protein produced by thyroid tissue), confirmed at follow-up. In low- to intermediate-risk differentiated thyroid cancer treated with surgery plus RAI, long-term remission rates are high and many patients require no further cancer treatment. Before-and-after scans show uptake in the thyroid bed on the pre-treatment scan and, ideally, no uptake on the post-treatment scan — confirming that residual tissue has been ablated.
Results vary with the original staging and risk category: a small papillary cancer treated early has a very different prognosis from a tumour with distant metastases. A trustworthy centre will discuss the realistic aim for your specific case — whether that is cure, long-term remission or disease control — rather than making a blanket promise. The oncology or nuclear medicine team should give you a written follow-up plan covering the schedule of thyroglobulin checks, neck ultrasounds and any further scans.
Risks and side effects of radioactive iodine therapy
Short-term side effects include nausea (usually mild and within the first day), neck tenderness or swelling if significant thyroid tissue remains, dry mouth and altered taste from salivary-gland exposure, and temporary fatigue from both the hypothyroid preparation and the treatment itself. Radiation sialadenitis (salivary-gland inflammation) is the most common side effect and is reduced by staying well hydrated and stimulating saliva. The NHS, the American Thyroid Association and the British Thyroid Association all publish patient information noting these risks.
Rarer concerns include temporary worsening of eye symptoms in patients who have Graves' disease (less relevant after thyroid cancer surgery), lacrimal gland involvement causing dry eyes, and — after very high cumulative doses — a small increased risk of secondary cancers (most evidence relates to doses used for treatment of metastatic disease). Bone marrow suppression is rare at standard ablation doses. Fertility effects are possible with high doses, which is why the advice on delaying conception applies. The treating team will discuss the dose-specific risks with you before treatment and obtain written consent.
How to choose a centre and questions to ask
Radioactive iodine therapy for thyroid cancer must be delivered by a licensed nuclear medicine facility with appropriate radiation-protection infrastructure, overseen by a nuclear medicine specialist or endocrinologist working alongside the oncology and endocrine surgery team. When comparing centres abroad, verify that the hospital holds national and, ideally, international accreditation (such as JCI), that the nuclear medicine department is separately licensed for therapeutic isotope use, and that there is a clear handover protocol to your home oncologist for follow-up. Check that the quote covers the whole-body scan as well as the treatment capsule. Use our free quote page to request written proposals from centres in Turkey; you can also read more about how the process works before submitting. For a wider view of oncology treatments in Turkey available at the same centres, see our oncology hub.
Red flags: a centre that quotes a dose without reviewing your pathology report and TSH level, that cannot confirm radiation-protection isolation arrangements, that lacks a clear post-treatment follow-up protocol, or that has no mechanism for communicating with your home oncologist. Questions to ask before you proceed:
- What dose (in millicuries or gigabecquerels) are you recommending for my case, and why?
- Will I need Thyrogen injections or levothyroxine withdrawal to prepare, and which do you recommend?
- How many nights of inpatient isolation does your radiation-protection licence require?
- What does the package include — scan, blood tests, Thyrogen, isolation room, discharge letter?
- How will the post-treatment whole-body scan report be shared with my oncologist at home?
- When should I expect my first follow-up thyroglobulin result, and who will interpret it?
- What is your protocol if I develop significant salivary-gland swelling or other side effects after returning home?
Conditions treated with Treatment of Thyroid Cancer with Radioactive Iodine
Hospitals with Oncology in Turkey
Frequently asked questions
It is a targeted internal radiation therapy in which a patient swallows a capsule of iodine-131. Because thyroid cells — and most differentiated thyroid cancer cells — absorb iodine selectively, the radiation concentrates inside any remaining thyroid tissue or cancer deposits and destroys them from within.
For differentiated (papillary and follicular) thyroid cancer, RAI after surgery is well supported by major clinical guidelines and reduces recurrence in intermediate- and high-risk patients. It does not work for medullary or anaplastic thyroid cancer, or for cancers that have lost the ability to absorb iodine.
Approximate ranges are €1,500 to €5,000 in Turkey, compared with €4,000 to €12,000 in the UK. The price depends on the prescribed dose, whether Thyrogen injections are used, the number of isolation nights and what scanning and blood tests are included.
The main recovery feature is a radiation isolation period of one to three days, during which you stay away from others, especially children and pregnant people. Fatigue from the hypothyroid preparation eases over two to four weeks once levothyroxine is restarted. Many people return to desk work within three to five days of treatment.
Common side effects include mild nausea, neck tenderness, dry mouth and altered taste from salivary-gland exposure. Staying well hydrated and sucking hard sweets in the first 24 hours reduces salivary-gland effects. Serious side effects are uncommon at standard ablation doses.
Swallowing the capsule takes only a few minutes. The preparation period (low-iodine diet plus TSH stimulation) takes one to three weeks beforehand, and the isolation period after treatment is one to three days. A follow-up whole-body scan is done two to seven days after treatment.
RAI is not suitable for medullary or anaplastic thyroid cancer, for very low-risk papillary microcarcinomas where surgery is considered curative alone, for radioiodine-refractory cancers, or for patients who are pregnant or breastfeeding. Men and women are advised to delay conception for several months after treatment.
Most patients plan for seven to ten days: a pre-treatment consultation and blood tests, one to three days of inpatient isolation after the capsule, the post-treatment scan, and a follow-up review before flying. Your exact stay depends on the dose, the centre's isolation requirements and your radiation level on discharge.
At standard remnant-ablation doses it has a well-established safety record confirmed by decades of clinical use. The American Thyroid Association and British Thyroid Association publish detailed patient guidance on risks. The main concerns at higher cumulative doses — used for metastatic disease — are salivary-gland effects and a small increase in secondary cancer risk.
RAI is thyroid-specific, delivering radiation from inside the cancer cells; it is the preferred adjuvant treatment for iodine-avid differentiated thyroid cancer after surgery. External-beam radiotherapy targets a wider field and is used for locally advanced disease, iodine-refractory recurrence or bone metastases where RAI is no longer effective.
Patient stories